DoD tests AI models that make it easy to switch from vendors like Palantir
SAN DIEGO - Gyre Therapeutics (NASDAQ:GYRE) reported fourth quarter revenue of $27.87 million and provided full year 2025 revenue guidance that fell short of analyst expectations.
The commercial-stage biotechnology company, which focuses on organ fibrosis treatments, expects 2025 revenue between $118 million to $128 million. This outlook represents 11.3% to 20.8% growth over 2024, but comes in below the $135.7 million analysts were anticipating.
Gyre’s 2025 guidance assumes the commercial launches of two new products - nintedanib for idiopathic pulmonary fibrosis and avatrombopag for chronic liver disease-associated thrombocytopenia. The company plans to begin selling these drugs in China this year to complement its existing ETUARY (pirfenidone) franchise.
For the fourth quarter of 2024, Gyre reported revenue of $27.87 million, up slightly from $27.1 million in Q4 2023. The company said ETUARY sales increased by $1 million YoY, offset partially by lower generic drug revenue.
"2025 is shaping up to be a pivotal year for Gyre across both our commercial-stage and clinical-stage portfolios," said CEO Han Ying. "Given our proven track record and extensive sales and marketing platform, we are confident in our ability to successfully launch and expand these two products in the PRC."
Gyre’s stock was unchanged in after-hours trading following the earnings release and 2025 outlook. The company ended 2024 with $51.2 million in cash and investments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.